-
2024-513300-34-00
1
2024-11-18
Advanced solid tumors harboring KRAS G12C mutation
-
2023-505232-36-00
5
2024-11-15
Essential thrombocythemia
-
2023-509230-19-00
7
2024-11-14
Advance solid tumors
-
2023-507178-41-00
9
2024-11-07
Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults
-
2023-510219-20-00
11
2024-11-04
Glycogen storage disease type Ia (GSDIa)
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2024-518419-20-00
4
2024-10-23
BRAF V600E mutated colorectal cancer
-
2024-515507-18-00
5
2024-10-09
Status epilepticus
-
2023-508338-33-00
5
2024-10-01
Chronic Inflammatory Demyelinating Polyneuropathy
-
2023-510136-36-00
1
2024-09-27
Advanced Non-Hodgkin’s Lymphoma
-
2023-507064-39-00
5
2024-09-26
generalized Myasthenia Gravis
-
2024-510715-30-00
4
2024-09-26
VEXAS
-
2024-517672-38-00
5
2024-09-20
Infection
-
2022-502139-20-00
4
2024-09-09
Mucositis and systemical inflammation, which is a treatment-related co
-
2023-504159-29-01
4
2024-09-03
Hyperglycaemia after renal transplantation
-
2024-515961-33-00
3
2024-09-02
No medical conditions or diseases will be examined, only healthy volun
-
2023-510415-19-00
4
2024-08-28
Acute Myeloid Leukemia
-
2023-505270-15-00
11
2024-08-19
Overweight and obesity
-
2024-513688-25-01
6
2024-08-19
periacetabular osteotomy
-
2023-506503-26-00
5
2024-07-31
Polyneuropathy, Inflammatory Demyelinating, Chronic
-
2024-515001-26-00
6
2024-07-25
Blood poisoning in patients with renal failure treated with hemodialys
-
2023-507684-19-00
5
2024-07-24
FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
-
2023-505794-32-04
5
2024-07-05
Type 1 diabetes
-
2024-513596-40-00
6
2024-06-28
Pleural empyema